Friday, July 10, 2026

pharma · Obesity, Overweight · Type 2 Diabetes

Eli Lilly and

Eli Lilly and clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
1876 Founded
55,860 Employees
EMA registrant Type
Company details
Status
Public
HQ
Lilly Corporate Center, Indianapolis, Indiana 46285, US
Founded
1876
Employees
55,860
Programs
107
Drugs
99
Patents
0
Intelligence · Clinical Programs

Eli Lilly and projects

3 ClinicalTrials.gov programs sponsored by Eli Lilly and.

Eli Lilly and has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. I4V-MC-JAJA

    Eli Lilly Co.

    Rheumatoid Arthritis

    approved small molecule active

    1 trial
  2. I6T-MC-AMCA

    Eli Lilly Co.

    severely active ulcerative colitis (US) and CD (Crohn’s disease)

    approved small molecule active

    1 trial
  3. SELPERCATINIB, SELPERCATINIB

    Eli Lilly Co.

    Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Eli Lilly and have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.